Is pregabalin (Pregabalin) effective for treating anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pregabalin is Effective for Treating Anxiety Disorders with Rapid Onset of Action

Pregabalin is an effective treatment for generalized anxiety disorder with rapid onset of action and favorable safety profile compared to benzodiazepines. 1, 2

Efficacy for Anxiety

Pregabalin has demonstrated significant efficacy for treating anxiety disorders:

  • In randomized controlled trials, pregabalin (150-600 mg/day) showed significant reduction in Hamilton Anxiety Rating Scale scores compared to placebo 1
  • Anxiolytic effects are observed as early as week 1 following initiation of treatment, which is more rapid than with SSRIs and SNRIs like paroxetine and venlafaxine 2
  • Efficacy has been demonstrated across various populations, including:
    • Adults with generalized anxiety disorder 1, 3
    • Elderly patients with anxiety disorders 4
    • Patients with severe anxiety 3

Dosing and Administration

  • Starting dose: 75 mg twice daily 5
  • Maximum daily dose: 600 mg 5
  • Dose regimen: 150-300 mg twice daily or 300 mg once daily 5
  • Dose adjustments required in patients with renal impairment 5

Advantages Over Other Anxiety Treatments

  • Rapid onset of action (within 1 week) compared to antidepressants 1, 2
  • No clinically significant withdrawal syndrome compared to benzodiazepines 1
  • Lower abuse potential than benzodiazepines 2
  • Minimal drug-drug interaction potential 2
  • Efficacy for both psychic and somatic symptoms of anxiety 4

Safety Considerations

Common Side Effects

  • Somnolence and dizziness are the most common adverse events 1, 3
  • Side effects are typically mild to moderate and self-limiting (median duration 4-16 days) 4

Special Populations

  • Effective and well-tolerated in elderly patients (≥65 years) 4
  • Dose adjustment required in patients with renal impairment 5

Precautions

  • Monitor for peripheral edema 5
  • Use with caution in patients with history of substance use disorders 5, 6
  • Potential for abuse exists, though lower than with benzodiazepines 6
  • Taper gradually over at least one week when discontinuing to minimize withdrawal symptoms 3

Alternative Uses

Beyond anxiety, pregabalin is also FDA-approved for:

  • Neuropathic pain conditions including diabetic peripheral neuropathy 7, 5
  • Postherpetic neuralgia 7, 5
  • Fibromyalgia 7

Clinical Algorithm for Anxiety Treatment

  1. First-line options:

    • Pregabalin (150-600 mg/day) for rapid onset of action
    • SNRI (duloxetine, venlafaxine) if comorbid depression present
    • CBT (non-pharmacological approach)
  2. Second-line options:

    • Switch to alternative first-line agent if inadequate response
    • Consider combination therapy for refractory cases
  3. Monitoring:

    • Assess response at 1-2 weeks (early efficacy expected)
    • Monitor for side effects, particularly somnolence and dizziness
    • Regular follow-up to assess continued efficacy and tolerability

Pitfalls and Caveats

  • Risk of abuse in patients with history of substance use disorders 6
  • Not recommended as first-line for patients with significant renal impairment without dose adjustment 5
  • Potential for misuse - case reports indicate patients may seek multiple prescriptions and experience euphoria 6
  • Gradual tapering required when discontinuing to avoid withdrawal symptoms 3

Pregabalin represents an important alternative to traditional anxiety treatments with its rapid onset of action and favorable side effect profile compared to benzodiazepines, making it particularly valuable for patients who need quick symptom relief or cannot tolerate other anxiety medications.

References

Research

Pregabalin in generalized anxiety disorder: a placebo-controlled trial.

The American journal of psychiatry, 2003

Research

Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder.

The British journal of psychiatry : the journal of mental science, 2008

Guideline

Neuropathic Pain Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.